Raymond Reilly, University of Toronto
Project Title: “Radiation Nanomedicine for Intraoperative Treatment of Glioblastoma Multiforme (GBM)”
In this project, we will study for the first time a new radiation nanomedicine for local treatment of glioblastoma multiforme (GBM) that could be administered at surgery in order to prevent tumour recurrence. The radiation nanomedicine is composed of gold nanoparticles (AuNPs) labeled with radioisotope, lutetium- 177 (177Lu) that emits short range radiation. The radiation nanomedicine is expected to eradicate small tumour deposits that the surgeon is unable to remove, but the short range of the radiation should also minimize normal brain toxicity. Although the surgeon aims to remove the entire brain tumour, any cancer cells that remain cause recurrence of GBM, and death from GBM. Our hope is that this radiation nanomedicine will present tumour recurrence. This approach to local treatment of brain tumours has never been previously studied. We will test the idea in mice implanted with human GBM in the brain that are treated by local administration of the radiation nanomedicine.
The effectiveness and normal tissue toxicity (including the normal brain) will be assessed. Our team includes neurosurgeons, Dr. James Rutka who treats GBM, thus if we are successful, we plan to advance this radiation nanomedicine to a Phase 1 clinical trial in patients with GBM.
What receiving this award means to Raymond:
“My research team is tremendously excited to receive support from Brain Tumour Foundation of Canada. This support will allow my team to test a new idea for preventing recurrence in patients with glioblastoma multiforme (GBM), which is one of the most difficult to treat and unfortunately one of the most common forms of brain cancer. Despite surgery, radiation and chemotherapy, recurrence remains a major challenge in treating GBM, contributing to the poor outcome in patients. We plan to study a new local form of radiation called a radiation nanomedicine that could be administered locally at the time of surgery to eradicate any remaining tumour and reduce the risk of recurrence. We could not study this new radiation nanomedicine without the support of Brain Tumour Foundation of Canada.”